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Circular dichroismThe surprising observation that a 10-residue class G⁎ peptide from apolipoprotein J, [113–122]apoJ, possesses
anti-inﬂammatory and anti-atherogenic properties prompted us to delineate its structural characteristics in
the presence of normal and oxidized lipid. Towards this, we have determined high-resolution structure of
[113–122]apoJ in solution using nuclear magnetic resonance (NMR) spectroscopy and studied its interaction
with lipids, including oxidized lipids, using a number of biophysical methods. Circular dichroism and NMR
studies established that in the presence of dodecylphosphocholine (DPC) micelle, this peptide adopts
amphipathic α-helical structure. The observed Nuclear Overhauser effects indicate that the amphipathic
helical structure of the peptide is stabilized by the N-terminal acetyl and C-terminal amide blocking groups.
We used isothermal titration calorimetry to measure binding enthalpy of the peptide with DPC micelle, an
oxidized lipid, 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdiA-PC), and the mixture of
these two lipids (5 mol% KOdiA-PC in DPC micelle). We ﬁnd that the peptide binding with DPC micelle is
associated with an enthalpy change (−16.75±0.16 Kcal/mol) much larger than that resulting from the
binding with KodiA-PC (−3.67±0.13 Kcal/mol). Incorporation of a small amount of KOdiA-PC (5 mol%) in
DPC micelle also results in the lowering of peptide binding enthalpy (−13.43±0.18 Kcal/mol). These results
are consistent with overall negative charge and altered conformational properties of oxidized sn-2 chain of
KOdiA-PC. Our results have unambiguously established the amphipathic α-helical structure of [113–122]apoJ
peptide in the presence of DPC micelle as well as its ability to bind oxidized lipid. These in vitro results help
explain the previously observed anti-inﬂammatory and anti-atherosclerotic properties of this peptide.chemical shift index; DPC,
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Cardiovascular disease (CVD) is the leading cause of morbidity and
mortality throughout the world. A signiﬁcant reduction in the LDL
cholesterol (LDL-C) levels has been achieved through statin therapy.
However, despite this reduction in LDL-C, the residual risk of CVDremains high [1]. This underscores the need for developing novel
therapeutic modalities to further reduce CVD risk.
Epidemiological studies have identiﬁed an inverse association
with the high-density lipoprotein cholesterol (HDL-C) levels and the
incidence of coronary heart disease in bothmen andwomen [2,3]. The
mechanism through which HDL-C confers its beneﬁcial effects has
been attributed to its ability to mediate cholesterol removal from
macrophages in a process termed as reverse cholesterol transport, as
well as its anti-inﬂammatory, anti-apoptotic, anti-oxidative, and anti-
thrombotic properties [4].
The effect of homologous plasma HDL on established atheroscle-
rotic lesions was studied in cholesterol-fed rabbits in 1990 by
Badimon et al. for the ﬁrst time [5]. This study provided the impetus
to study the anti-atherogenic potential of a number of HDL-Cmimetic.
Apolipoprotein A-I (apoA-I) is the major apolipoprotein of HDL
comprising of ~70% of all the apolipoproteins present in HDL.
Apolipoprotein A-IMilano (apoA-IMilano) is a genetic variant of apoA-I
with an arginine-to-cysteine substitution at position 173 present in
individuals with a very low HDL-C level and no obvious signs of
Fig. 1. [113–122]apoJ is a class G* helix. Helical wheel (left) and helical net (right)
diagrams of [113–122]apoJ. The primary amino acid sequence of [113–122]apoJ peptide
is shown above helical wheel and helical net diagrams. Ac (acetyl) and NH2 (amide) are
blocking groups. Color codes are as follows: acidic, red; basic, blue; hydrophobic, thick
black; neutral, orange.
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plex (ETC-216; recombinant apoA-IMilano/1-palmitoyl-2-oleoyl phos-
phatidylcholine complexes) administered intravenously for 5 doses at
weekly intervals produced signiﬁcant regression of coronary athero-
sclerosis as measured by intravascular ultrasound [8]. Short-term
infusions of reconstituted HDL (CSL-111; CSL-111 is reconstituted
HDL consisting of apolipoprotein A-I from human plasma combined
with soybean phosphatidylcholine) in the ‘Effect of rHDL on
Atherosclerosis-Safety and Efﬁcacy’ (ERASE) trial resulted in no
signiﬁcant reductions in percentage change in atheroma volume or
nominal change in plaque volume compared with placebo but did
result in statistically signiﬁcant improvement in the plaque charac-
terization index and coronary score on quantitative coronary
angiography [9].
ApoA-I is a 243-amino-acid residue protein and, therefore, difﬁcult
and expensive to produce in large quantities required for therapeutic
applications. For this reason, there has been a great deal of interest in
developing apoA-I mimetic peptides that are much shorter in length
and, therefore, easy to synthesize in much larger quantities. Our
laboratory has pioneered the development of such peptides. Garber
et al. [10] showed for the ﬁrst time that an 18-residue apoA-I mimetic
class A amphipathic helical peptide, named 5F (because of the
presence of ﬁve Phe residues on the nonpolar face), has anti-
atherosclerotic properties in vivo. When an apoA-I mimetic peptide
synthesized from D -amino acids (D-4F; so named because of the
presence of four Phe residues on the nonpolar face) was given orally
to LDL receptor-null mice on a Western diet, atherosclerotic lesions
decreased by 79% [11]. It was shown later that the mechanism of
action of oral D-4F in apoE-null mice involves rapid formation of small
cholesterol-containing particles of 7 to 8 nm, with pre-β mobility
enriched in apoA-I and paraoxonase activity. As a result, lipoprotein
lipid hydroperoxide are reduced, HDL becomes anti-inﬂammatory,
and HDL-mediated cholesterol efﬂux and reverse cholesterol trans-
port from macrophages are stimulated [12]. Preliminary clinical data
suggest that, in patients with established coronary artery disease, a
single oral dose of D-4F is both safe and tolerable and reduces the HDL
inﬂammatory index [13].
Both 5F and 4F peptides are de novo designed peptides with no
sequence homology to apoA-I or any other apolipoprotein. Both these
peptides are class A amphipathic helical peptides [14]. The ability of
these peptides to inhibit atherosclerosis in mouse models has been
closely correlated with their ability to inhibit LDL-induced monocyte
chemotactic activity (MCA) in a human artery wall co-culture [15]. An
approach to the design of smaller anti-atherogenic peptides comes
from the analysis of naturally occurring anti-atherogenic apolipopro-
tein sequences. Apolipoprotein J (apoJ) is a glycoprotein and exists in
the plasma associated with HDL [16]. ApoJ has been shown to bind
inﬂammatory lipids and inactivate them; LDL added to human artery
wall cells in the presence of apoJ could not induce MCA [17]. To test
the hypothesis that short amphipathic helical sequences in apoJ could
mimic its activity, the apoJ sequence was analyzed using an in house-
developed computer program called LOCATE [18]. This program
identiﬁed 17 potential class G* amphipathic helices in themature apoJ
protein, including [113–122]apoJ [19]. It is important to note that all
of the exchangeable apolipoproteins except apolipoproteins A-II and
C-I possess class G* helices. Class G* helices are characterized by a lack
of clustering of positively charged amino acids at the polar–nonpolar
interface and negatively charged amino acids at the center of polar
face as present in class A amphipathic helices, a high mean
hydrophobic moment, and moderately high nonpolar face hydropho-
bicity [14]. Fig. 1 shows the helical wheel and helical net diagrams of
[113–122]apoJ. Unlike class A amphipathic helices, the lipid associ-
ating properties of class G* helices have not been studied in detail.
This peptide, synthesized using D-amino acids, renders HDL anti-
inﬂammatory in both mice and monkeys and dramatically reduces
atherosclerosis in apoE-null mice [19]. It was further shown that co-administration of L-[113–122]apoJ and niclosamide improved the
ability of HDL to inhibit LDL-induced monocyte chemotactic activity,
known as HDL inﬂammatory index, in endothelial cell cultures to a
degree similar to L-4F given with niclosamide and achieved an HDL-
inﬂammatory index comparable to that obtained with normal human
anti-inﬂammatory HDL [20]. Niclosamide (a chlorinated salicylanilide
used as molluscicide, antihelminthic, and lampricide) has been shown
to associate with L-4F and prevent its trypsin digestion [20].
Many of the known anti-inﬂammatory and anti-atherogenic
peptides are amphipathic helical peptides [21–23]. The present
studies were undertaken to correlate the biological activities of
[113–122]apoJ with its structure and ability to bind lipids, including
oxidized lipids. Speciﬁcally, since [113–122]apoJ is only 10-residue
long, we asked the question if this peptide could also adopt an
amphipathic α-helical structure and associate with lipids, particularly
oxidized lipids.
2. Experimental methods
2.1. Materials
The sequence for [113–122]apoJ is Ac–Leu–Val–Gly–Arg–Gln–
Leu–Glu–Glu–Phe–Leu–NH2. The peptide is blocked at the N- and
C-termini with acetyl (Ac-) and amide (-NH2) groups, respectively.
[113–122]apoJ was synthesized from all L -amino acids by automated
solid-phase synthesis using the Fmoc strategy, and puriﬁed by
reverse-phase HPLC as previously described [19]. The purity of the
peptide was conﬁrmed by analytical reverse-phase HPLC and MALDI-
TOF mass spectrometry.
Protonated dodecylphosphocholine (DPC) was obtained from
Avanti Polar Lipids, Inc. (Alabaster, Alabama). Perdeuterated DPC
(D38, 98%) was obtained from Cambridge Isotope Laboratories
(Andover, MA). 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphati-
dylcholine (KOdiA-PC) was obtained from Cayman Chemical Compa-
ny (Ann Arbor, MI) and used without further puriﬁcation.
2.2. Circular dichroism (CD) spectroscopy
The CD spectra were recorded using JASCO J-815 CD spectrometer
equipped with a Peltier type temperature control system (JASCO
model PTC-423S/15) and interfaced to a personal computer. The
instrument was calibrated with (1S)-(+)-10-camphorsulfonic acid.
The CD spectra weremeasured from 260 to 190 nm every 0.5 nmwith
4-s averaging per point and a 2-nm bandwidth. A 0.1-cm path length
cell was used for obtaining the spectra. The CD spectra were signal
Fig. 2. [113–122]apoJ forms helical structure in the presence of DPC micelle; helicity is
reduced in the presence of KOdiA-PC. Far-UV CD Spectra of [113–122]apoJ in
phosphate-buffered saline (PBS, pH 7.4) and in the presence of DPC (lipid-to-peptide
molar ratio, 125:1) and KOdiA-PC (lipid-to-peptide molar ratio, 25:1) at 37 °C. There
was no change in the CD spectra above the lipid-to-peptide molar ratios used. Peptide
concentration was 0.1 mg/ml.
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the CD spectra were recorded at 37 °C. Peptide concentration of
0.1 mg/ml was used for obtaining CD spectra. The mean residue
ellipticity, [Θ]MRE (deg cm2 dmol−1), was calculated using the
following equation:
Θ½ MRE = MRW × Θð Þ= 10clð Þ
where MRW is the mean residue weight (molecular weight of the
peptide divided by the number of amino acids in the peptide), Θ is the
observed ellipticity in degrees, c is the concentration of the peptide in
grams per milliliter, and l is the path length of the cell in centimeters.
The secondary structure of the peptide was analyzed using the
programs CDPro (http://lamar.colostate.edu/~sreeram/CDPro) and
K2D (http://www.embl-heidelberg.de/~andrade/k2d.html) [24].
2.3. Isothermal titration calorimetry (ITC)
ITC was used to measure the binding enthalpy (ΔHbind) of peptide
with DPC micelle, KOdiA-PC, and a mixture of KOdiA-PC (5 mol%) and
DPCmicelle using a VP-ITCmicrocalorimeter (Microcal, Northampton,
MA). Measurements were made at 37 °C and pH 7. An excess site
method was employed wherein a high concentration of DPC, KOdiA-
PC, or the mixture of the two were placed in the sample cell and
titrated with a low concentration of peptide. This method eliminates
the saturation of binding sites of the lipid and results in the full heat of
binding, (ΔHbind), evolved upon each injection. Speciﬁcally, titrations
were performed by injecting 10 μl aliquots of the peptide solution at a
concentration of typically 200–250 μM into the calorimeter cell
containing the lipid at a concentration of 5–15 mMwith 200-s resting
time between each injection. The heats of dilution for the peptide
were determined by injecting the peptide solution into pure buffer
and subtracted from the data prior to analysis. The data were analyzed
by integrating the area of each injection peak and plotted using the
Origin 7.0 software integrated into the VP-ITC instrument software.
The ﬁrst data point was removed and ΔHbind was calculated by taking
the averaged integrated value for the remaining injections.
2.4. NMR sample preparation
Protonated and perdeuterated DPCmicelle were prepared in 5 mM
KH2PO4 (pH 5.5). KodiA-PC was prepared by evaporating ethanloic
solution of the lipid under a stream of nitrogen gas. Residual solvent
was removed by placing the sample under high vacuum at room
temperature overnight. Dried lipid sample was suspended in 5 mM
KH2PO4 (pH 5.5). Lyophilized dry peptide was dissolved separately in
5 mM KH2PO4 (pH 5.5). An appropriate volume of peptide solution
was added to either DPC micelle or KOdiA-PC and the mixture was
incubated overnight at 37 °C. The pH of the ﬁnal solution was 5.5. The
ﬁnal peptide concentration in solution was between 1 and 2 mM. The
lipid-to-peptide molar ratio (125:1 for DPC and 25:1 for KOdiA-PC)
was identical with that used in the CD studies. This lipid-to-peptide
ratio was selected based on the CD studies that indicated no further
change in the secondary structure of the peptide above this ratio.
2.5. NMR measurements and structure calculations
1D- and 2D-1H NMR experiments were performed either on a
Bruker Avance-600 NMR system with a TCI CryoProbe or an Avance-
500 NMR spectrometer at 37 °C. Mixing times of 200 or 300 ms were
used in NOESY, and 80-ms spin-lock timewas used in total correlation
spectroscopy (TOCSY) measurements. 2D data sets were collected
with 1024 complex t2 points with 512 t1 increments. States-time
proportional phase incrementation (TPPI) was employed for frequen-
cy discrimination in the indirect dimension. Chemical shifts were
referenced with respect to sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) (0.0 ppm) used as an internal standard. Water
suppression was accomplished either by presaturation or by using
the WATERGATE (WATER suppression by GrAdient-Tailored Excita-
tion) pulse sequence [25].
31P NMR experiments were conducted using Bruker Avance
500 MHz system equipped with a TBI broadband probe. 2048 Scans
were used to acquire each 31P spectrum, at a temperature of 310 K.
The samples were allowed to equilibrate in the probe for 30 min
before acquisition was begun. The acquired spectra were referenced
using 85% phosphoric acid as an external standard (0.0 ppm).
The NMR data were processed ofﬂine using the program FELIX
(version 2007) (Felix NMR Inc., San Diego, CA). NMR structures were
calculated using X-PLOR (online) version 3.851. Structure calculation
protocol involved (a) generation of a “template” coordinate set; (b)
bound smoothing, full structure embedding, and regularization to
produce a family of 200 distance geometry (DG) structures; (c)
simulated annealing regularization and reﬁnement for embedded
distance geometry structures; and (d) simulated annealing reﬁne-
ment, as described previously [26]. The best 100 structures were
selected for further analysis on the basis of their least restraint
violation, low energy and Ramachandran plot quality. Average
coordinates of the accepted structures were energy minimized using
200 cycles of conjugate gradient energy minimization. All the NMR
constraints were enforced during energy minimization.
On the basis of cross-peak intensities in the NOESY spectra,
recorded with mixing times of 200 ms, the NOE distance constraints
were classiﬁed as following. For NOEs involving intra-residue and
sequential NH, αH, and βH protons, a distance constraint of 2.0–2.5 Å
for strong, 2.0–3.0 Å for medium, and 2.0–4.0 Å for weak NOEs was
used; for medium- or long-range NOEs involving NH, andαH protons,
a distance constraint of 2.0–4.0 Å was used; for NOEs involving
medium- or long-range sidechain protons, a distance constraint of
2.0–5.0 Åwas used. Pseudoatom corrections, where appropriate, were
added to the upper distance bounds as described previously [27].
Based on the difference (Δδ) in the observed and “coil” NH proton
chemical shifts, H-bond (H–O) distances were calculated as described
earlier [28,29]. These H-bond distances were included as additional
Table 1
Secondary structure analysis of [113–122]apoJ in buffer and in the presence of DPC (lipid-to-peptide molar ratio, 125:1) and KOdiA-PC (lipid-to-peptide molar ratio, 25:1).
CDPro H(r) H(d) S(r) S(d) Trn Unrd RMSD
SELCON3
[113–122]apoJ:Buffer 0.058 0.129 0.068 0.07 0.246 0.401 1.956
[113–122]apoJ:DPC (10 mM) 0.752 0.101 0.017 0.04 0.035 0.04 2.37
[113–122]apoJ:KOdiA-PC (2 mM) 0.124 0.119 0.156 0.098 0.228 0.306 0.337
Continll
[113–122]apoJ:Buffer 0.048 0.141 0.058 0.08 0.268 0.399 0.179
[113–122]apoJ:DPC (10 mM) 0.69 0.271 0 0 0.004 0.031 0.408
[113–122]apoJ:KOdiA-PC (2 mM) 0.162 0.173 0.007 0.044 0.271 0.343 0.237
CDSSTR
[113–122]apoJ:Buffer 0.074 0.135 0.133 0.08 0.253 0.299 0.467
[113–122]apoJ:DPC (10 mM) 0.585 0.19 0.034 0.03 0.043 0.108 0.676
[113–122]apoJ:KOdiA-PC (2 mM) 0.313 0.139 0.124 0.0085 0.128 0.214 0.595
K2D Alpha helix Beta strand
[113–122]apoJ:Buffer 0.081 0.241
[113–122]apoJ:DPC (10 mM) 0.849 0.006
[113–122]apoJ:KOdiA-PC (2 mM) 0.105 0.291
H(r), regular helix; H(d), distorted helix; S(r), regular sheet; S(d), distorted sheet; Trn, turn; Unrd, unordered; RMSD, root–mean–square deviation between the calculated and
experimental CD spectra.
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were based on the difference in the observed and “coil” CαH proton
chemical shifts [28,29]; a minimum deviation of 40° was allowed in
the dihedral constraints.Fig. 3. [113–122] apoJ binding with DPC and KodiA-PC is associated with a favorable enthalp
5 mol% KOdiA-PC in DPC micelle (C), determined using isothermal titration calorimetry (IT2.6. Molecular modeling
Molecular modeling was performed using the program SYBYL
(version 7.2) (Tripos, Inc., St. Louis, MO).y change. Enthalpy of [113–122] apoJ binding with DPC micelle (A), KOdiA-PC (B), and
C).
Fig. 4. [113–122]apoJ adopts different conformation under different solvent environ-
ments. Aromatic/amide region of the 1H NMR spectrum of [113–122]apoJ in 5 mM
potassium phosphate (pH 5.5) (A), DPC (lipid-to-peptide molar ratio, 125:1) (B), and
KOdiA-PC (lipid-to-peptide molar ratio, 25:1) (C). All the spectra were obtained at
500 MHz and 37 °C and processed in an identical manner.
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3.1. Circular dichroism studies
Fig. 2 shows the far-UVCD spectra of [113–122]apoJ in PBSand in the
presence of DPC micelle (lipid-to-peptide molar ration 125:1) and
KodiA-PC (lipid-to-peptide molar ratio 25:1). There was no further
change in the CD spectra upon increasing the above lipid-to-peptide
molar ratios (results not shown). The secondary structure of [113–122]
apoJ was analyzed using CDPro and K2D. The results are shown in
Table 1. Based on the analysis of CD spectra, it is evident that [113–122]
apoJ adopts a largely helical structure in the presence of DPC micelle
(Table 1). However, the helical content of [113–122]apoJ is much
reduced in the presence of KOdiA-PC (Fig. 2, Table 1).
3.2. Isothermal titration calorimetry
Binding of [113–122]apoJ to DPC, KOdiA-PC, and a mixture of the
two lipids (5 mol% KOdiA-PC in DPC micelle) was further probed
using ITC (Fig. 3). The peptide was titrated into a concentrated
solution of lipid. In this method, saturation is not reached and each
injection results in the total enthalpy of reaction (ΔH) for each injection.
The ΔH for the reaction was found to be −16.7±0.16, −3.7±0.13,
and−13.4±0.18 Kcal/mol for DPC, KOdiA-PC, and 5 mol% KOdiA-PC in
DPC, respectively, by taking the average of 15 injections (Fig. 3).
3.3. Nuclear magnetic resonance studies
Fig. 4 shows the aromatic/amide region of the 1H NMR spectra of
[113–122]apoJ in buffer (A), DPC micelle (B), and in the presence of
KOdiA-PC (C). All the 1H NMR spectra were obtained under identical
conditions (500 MHz, 37 °C) and processed using identical window
functions. There is a greater dispersion of amide protons (7.6–8.7 ppm)
in the presence of DPC micelle (B) than in buffer (A). It is interesting
to note that the amide protons are less dispersed in the presence of
KOdiA-PC (C) than in the presence of DPC micelle (B), but more
dispersed than in buffer (A), indicating that the peptide adopts different
conformations in different environments.
Fig. 5 compares the 1H NMR spectra of DPC micelle alone (A),
[113–122]apoJ in the presence of DPC micelle (B), KodiA-PC alone (C)
and [113–122]apoJ in the presence of KOdiA-PC (D). The choline
methyl 1H NMR signal of DPC molecules shows upﬁeld shift in the
presence of [113–122]apoJ (from 3.249 ppm to 3.202 ppm) (Fig. 5A
and B). The upﬁeld shift of the cholinemethyl proton signal, indicative
of a more hydrophobic environment, is consistent with the binding of
the [113–122]apoJ with the DPC micelle. The choline methyl 1H NMR
signal of KOdiA-PC, similar to that of DPC micelle (Fig. 5A and B),
shows upﬁeld shift in the presence of [113–122]apoJ (from 3.250 to
3.194 ppm) (Fig. 5C and D). The upﬁeld shift of the choline methyl
proton signal is consistent with the binding of [113–122]apoJ with
KOdiA-PC.
Interaction of [113–122]apoJ with KOdiA-PC was further probed
using 31P NMR spectroscopy. 31P NMR spectra of DPC micelle, KOdiA-
PC, and a mixture (lipid-to-peptide molar ratio, 25:1) of KOdiA-PC
and [113–122]apoJ are compared in Fig. 6. Compared to DPC micelles,
KOdiA-PC exhibits broader 31P NMR spectrum (Fig. 6). This is
presumably because of the close spatial proximity of the truncated
sn-2 chain with the phosphate group [31] resulting in the restricted
mobility of the phosphate group in KodiA-PC compared to that in DPC
micelle.
Addition of [113–122]apoJ to KOdiA-PC results in the appearance of
an isotropic narrow 31P signal, superimposed on the broad KOdiA-PC
signal (Fig. 6). The narrow 31P signal presumably arises from the
KOdiA-PC complexed with [113–122]apoJ.
A combination of two-dimensional 1H total correlation spectros-
copy (TOCSY; spectrum not shown) and nuclear Overhauser spec-troscopy (NOESY) was used to make sequence-speciﬁc resonance
assignments of the individual amino acids in [113–122]apoJ [32].
Proton chemical shifts are related to the secondary structures of
peptides and proteins [28,29]. The plots of the difference between the
observed chemical shift and the coil chemical shift (Δδ=δobserved−δcoil)
for the CαH in [113–122]apoJ in the presence of DPCmicelle are shown in
Fig. 7. It is evident that all of the CαH protons show an upﬁeld shift
compared to the randomcoil values, indicating a predominantlyα-helical
secondary structure of [113–122]apoJ in the presence of DPC micelle.
Fig. 8A and B shows the amide/aromatic proton region and the
ﬁngerprint region, respectively, of the NOESY spectrum of [113–122]
apoJ obtained using a mixing time of 200 ms in the presence of DPC
micelle. Sequential dNN(i, i+1) NOESY cross-peaks for all the residues
in [113–122]apoJ are identiﬁed in Fig. 8A. In addition, dNN(i, i+2)
cross-peaks were observed for Gly3/Gln5, Leu6/Glu8, Glu7/Phe9, and
Glu8/Leu10 pairs and are labeled in Fig. 8A. In Fig. 8B, intraresidue HN/
CαH NOEs for all the residues in [113–122]apoJ are labeled. The
methyl protons of the N-terminal acetyl protecting group showed
NOEs to Leu1, Val2, Gly3, and Arg4 (Fig. 8B). The observed (i, i+1),
(i, i+2), (i, i+3), and (i, i+4) NOEs are schematically shown in
Supplement Figure 1.
Because of the conformational equilibrium present in solution,
NMR data cannot be interpreted in terms of a single structure as is the
case with structure determined using X-ray crystallography. Howev-
er, the calculation of a limited number of structures compatible with
the observed NMR data is a useful way to visualize the features of the
family of structures present in the conformational ensemble. The
distance and dihedral constraints were used to calculate NMR
structures of [113–122]apoJ in the presence of DPC micelle. Starting
from a set of initial 300 extended structures of [113–122]apoJ, 100
structures were accepted based on the following criteria: (a) no NOE
violations N0.5 Å, (b) no dihedral angle violations N5°, (c) rms
difference for bond deviations from ideality b0.01 Å, and (d) rms
difference for angle deviations from ideality b2°. To obtain the
average NMR structure, average coordinates of the 100 accepted
structures of [113–122]apoJ were energy-minimized. All the distance
and the dihedral angle constraints were enforced during the energy
Fig. 5. [113–122]apoJ binding results in an upﬁeld shift of the methy proton signal of lipid choline headgroup. Methyl proton resonance of DPC (A and B) and KodiA-PC (C and D)
choline headgroups shift upﬁeld as a result of [113–122]apoJ binding. 1H NMR spectra were obtained and processed as described in Fig. 4.
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the 100 accepted NMR structures and the energy-minimized average
structure of [113–122]apoJ are summarized in Table 2. The 100Fig. 6. Addition of [113–122]apoJ to KOdiA-PC results in the appearance of an isotropic
narrow 31P signal. 31P NMR spectra of DPC micelle (A), KOdiA-PC (B), and mixture of
[113–122]apoJ and KOdiA-PC (lipid-to-peptide molar ratio, 25:1) (C). 2048 Scans were
used to acquire each 31P spectrum, at a temperature of 310 K. The samples were
allowed to equilibrate in the probe for 30 min before acquisition was begun. The spectra
were processed with exponential multiplier window functions, using a line broadening
value of 10 Hz. The spectra were referenced using 85% phosphoric acid (0.0 ppm). The
narrow 31P signal, indicated by an arrow (C), presumably arises from the KOdiA-PC
complexed with [113–122]apoJ.accepted structures were superimposed onto the energy-minimized
average structure using MATCH (SYBYL, version 7.2). The program
MATCH performs an automatic least squares ﬁt of two molecules that
differ only in the coordinates of their atoms. Fig. 9 shows
superposition of the Cα atoms of all the 100 accepted structures on
the energy-minimized average NMR structure of [113–122]apoJ. The
energy-minimized average structure is shown as a ribbon/tube
(Fig. 9). Side chains of the energy-minimized average structure of
[113–122]apoJ are also shown in Fig. 9.
4. Discussion
An understanding of detailed structure and lipid-associating
properties of anti-inﬂammatory and anti-atherogenic peptides isFig. 7. CαH proton chemical shifts indicate predominantlyα-helical secondary structure
of [113–122]apoJ in the presence of DPC micelle. A plot of the ΔδCαH (δobserved–δcoil)
chemical shift for all the residues in [113–122]apoJ. Note that the CαH protons show an
upﬁeld shift compared to the corresponding coil values, indicating α-helical structure.
Random coil chemical shifts used were those reported in K. Wuthrich (1986), NMR of
Proteins and Nucleic Acids, John Wiley & Sons, Inc., New York.
Fig. 8. NOESY spectrum of [113–122]apoJ in DPC micelle shows characteristic NOEs of
an α-helical structure. Amide/aromatic (A) and ﬁngerprint (B) regions of the NOESY
spectrum (mixing time 200 ms) of [113–122]apoJ in DPC micelle in 5 mM potassium
phosphate, pH 5.5, at 37 °C. The spectrum was obtained as described in Fig. 4. In A,
sequential dNN(i, i+1) and the observed dNN(i, i+2) NOEs are labeled. Also labeled are
the observed NOEs between residues Phe9 and Leu10 and C-terminal amide (NH2)
blocking group. In B, intraresidue HN/HA NOEs as well as observed NOEs between
N-terminal acetyl group (ACE) and other peptide protons are labeled.
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highly active peptide analogs. LOCATE [18] analysis, as well as helical
wheel and helical net diagrams (Fig. 1), predicts an amphipathic
α-helical structure of [113–122]apoJ. Results of CD analysis indicate
that indeed in the presence of DPC micelle [113–122]apoJ adopts an
α-helical structure (Fig. 2, Table 1). Anα-helical structure is stabilized
by the formation of i+4→ i hydrogen bonds. Short polypeptides
generally do not adopt an α-helical structure in solution as the
hydrogen bond formation does not occur because of the high entropic
cost associated with the folding of the polypeptide chain. However,within a hydrophobic environment, e.g., within the hydrophobic
pockets of proteins, the α-helical secondary structures of even small
peptide fragments can be stabilized through local inter-residue
interactions. The water–lipid interface of the DPC micelle in the
present study provides such an environment for facilitating the
formation and stabilization of α-helical structure of [113–122]apoJ
peptide.
Results of ITC experiments indicate that binding of [113–122]apoJ
with lipids is accompanied by a favorable enthalpy change (Fig. 3). It is
interesting to note, however, that the change in enthalpy is much
smaller for the interaction of [113–122]apoJ with KOdiA-PC (Fig. 3B).
Even addition of 5 mol% of KOdiA-PC to DPC micelle lowers the
enthalpy of interaction (Fig. 3C). It is important to note that the
overall electrical charge of [113–122]apoJ at neutral pH is minus one
(−1). The sn-2 side chain of KOdiA-PC that ends in a carboxyl group,
according to the “Whisker” model [31], will produce a water–lipid
interface that is overall negatively charged. This is in contrast to the
zwitterionic nature of the water–lipid interface in case of DPC. An
overall negatively charged peptide is likely to interact weakly with an
overall negatively charged lipid surface compared to a zwitterionic
surface. This is shown schematically in Fig. 10.
Although CD results indicated that [113–122]apoJ is predomi-
nantly α-helical in the presence of DPC micelle (Fig. 2, Table 1),
conformation of individual residues cannot by obtained using this
method. To obtain a high-resolution three-dimensional structure of
[113–122]apoJ in the presence of DPC micelle, two-dimensional (2D)
1H NMR experiments were carried out. The 1H NMR chemical shifts in
peptides and proteins are dependent on the secondary structure, e.g.,
CαH protons move upﬁeld (relative to their random coil value) on
helix formation [28,29]. An inspection of Fig. 7 reveals that all the CαH
protons in [113–122]apoJ show an upﬁeld shift compared to random
coil values consistent with an α-helical secondary structure.
The α-helical secondary structure of [113–122]apoJ was further
evident by the observation of sequential andmedium range (dNN(i, i+1)
and dNN(i, i+2) NOEs (Fig. 8A). In addition, several other long range
(i, i+3) NOEs were also observed (Figure S1) consistent with the
α-helical secondary structure of [113–122]apoJ in the presence of DPC
micelle. The amphipathic α-helical structure of [113–122]apoJ peptide is
evident in Fig. 9, with the hydrophobic residues clustered on one face
(nonpolar) of the helix and charged and polar residues clustered on the
opposite face (polar) of the helix.
We have shown previously that both N-terminal acetyl and
C-terminal amide blocking groups stabilize α-helical structure in
peptides by allowing the formation of two additional H-bonds (one at
each end) between residues i (acceptor) and i+4 (donor) compared
with the unblocked peptide [26,33]. Consistent with our earlier
observations, CD analysis of unblocked [113–122]apoJ peptide
(without acetyl and amide blocking groups) revealed reduced helicity
(based on K2D analysis, 44% in the presence of DPC micelle). In
addition, we found that the blocking groups are involved in the inter-
residue interactions as well (Fig. 8A and B) presumably further
stabilizing the α-helical structure of [113–122]apoJ. The N-terminal
acetyl group shows NOEs to Leu1, Val2, Gly3, and Arg4 backbone NH
protons (Fig. 8B), whereas C-terminal amide group shows NOEs to
Phe9 and Leu10 backbone NH protons (Fig. 8A). It is worthy of note
that, in addition to helix stabilization, N-terminal acetylation
increases the overall hydrophobicity of the peptide also facilitating
its partitioning from the aqueous phase into the lipid phase.
Howwill the information obtained in the present work help explain
the observed anti-inﬂammatory and anti-atherosclerotic properties of
[113–122]apoJ?Dyslipidemia is associatedwith oxidative stress and the
generation of biologically active oxidized lipids. Biologically active
oxidized phospholipids can initiate and modulate many of the cellular
events attributed to the pathogenesis of atherosclerosis [34]. A novel
family of atherogenic oxidized choline glycerophospholipids
(oxPCCD36) that are formed during the oxidization of low-density
Table 2
Structural statistics for the 100 accepted (bSAN) and the energy minimized average
(bSAN r) NMR structures of [113–122]apoJ associated with DPC micelle.
Experimental restraints
Intraresidue NOEs 41
Sequential NOEs 23
Medium and long range NOEs
(i, i+2; i, i+3; and i, i+4)
19
Other NOEs 8
Hydrogen bonds (H–O distance) 7
Φ angles 9
Ψ angles 8
Total 115
Mean rmsda from experimental restraints bSAN± SDb
Distance restraints (Å) 0.022±0.004
Dihedral angle (°) 0.054±0.123
Mean rmsd from ideal geometry bSAN± SD
Bonds (Å) 0.001±0.000(4)
Angles (°) 0.473±0.029
Impropers (°) 0.374±0.038
Ramachandran statistics from PROCHECK-NMRc
Residues in most favored α-helical region 100 %
rmsd from the average structure (Å)
Backbone N, Cα, C 0.296
All heavy atoms 1.371
Pairwise rmsd analysis
Average backbone pairwise rmsd (Å) 0.420 (±0.122)
Averagenon-hydrogenatompairwise rmsd(Å) 1.875 (±0.264)
X-PLOR potential energies (kcal/mol)
bSAN± SD (bSAN r)d
Eoverall 15.039±2.489 14.774
Ebond 0.378±0.147 0.408
Eangle 11.095±1.446 10.971
Eimpropers 1.969±0.424 1.809
Evdw 0.328±0.532 0.0
ENOE 1.248±0.522 1.585
Ecdih 0.018±0.072 0.0
a Root–mean–square deviation.
b Standard deviation.
c Ref. [41].
d 200 Cycles of conjugate gradient minimization were used. All of the NMR
constraints were enforced during the energy minimization of the average coordinates.
Fig. 10. A proposed model of initial interaction of [113–122]apoJ with DPC and KOdiA-
PC. A schematic representation of the binding of [113–122]apoJ with DPC (left) and
KOdiA-PC (right). The thickness of the red arrow indicates strength of binding. Because
of the overall negative charge of [113–122]apoJ, it is proposed to bind weakly with
negatively charged KOdiA-PC than with zwitterionic DPC.
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enhanced oxidative stress have been isolated and structurally charac-
terized [35,36]. oxPCCD36 serves as high-afﬁnity ligands for the
macrophage scavenger receptor CD36 and facilitates macrophage
foam cell formation through recognition and uptake of oxidized low-
density lipoprotein by CD36 [37]. It has been suggested that theFig. 9. Amphipathic α-helical structure of [113–122]apoJ in the presence of DPC micelle. A re
minimized average structure of [113–122]apoJ. N-terminus is towards the top and C-terminu
side chains along the long axis of the α helix.selectively blocking the interaction between oxPCCD36 andCD36might
be a useful therapeutic approach against atherothrombotic diseases
[38]. The conformationof a prototypic high-afﬁnity CD36 ligand, KOdiA-
PC, near the hydrophobic–hydrophilic interface within membrane
bilayers was probed by determining multiple critical internuclear
distances using NOESY and it was shown that the truncated oxidized
sn-2 fatty acid chain of KOdiA-PCwithinmembranes protrudes into the
aqueousphase (the “whisker”model) [31]. Based on these observations,
it was hypothesized that this allows a direct physical access of the
KOdiA-PC to the cell surface macrophage CD36 receptor [31]. It was
shown further that this unusual conformation for an oxidized
phospholipid within a membrane may not be unique to KOdiA-PC but
rather might represent a more global phenomenon of oxidizedlaxed eye stereo view of the 100 accepted NMR structures superimposed on the energy
s is towards the bottom of the page. Note the distinct segregation of nonpolar and polar
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recognition receptor and molecular pattern ligand [39,40].
Based on the results obtained using different techniques (CD, ITC,
and 1H and 31P NMR), we have shown that [113–122]apoJ is able to
bind KOdiA-PC, an oxidized lipid. It is likely that a potential
mechanism of anti-atherogenic and anti-inﬂammatory property of
[113–122]apoJ is due to its association with the oxidized lipids. As
proposed earlier for 4F [33], this may allow the sequestration of the
oxidized phospholipids by [113–122]apoJ, thereby preventing inter-
action of oxidized phospholipids with their receptor (e.g., CD36).
In summary, this study has signiﬁcantly improved our knowledge
about the structure and molecular interactions of an anti-atherogenic
and anti-inﬂammatory class G* amphipathic helix, [133–122]apoJ,
with normal as well as oxidized lipids. We have demonstrated
unambiguously that even a relatively short 10-residue peptide can be
induced into α helix conformations in aqueous solution through
binding to lipid. The amphipathic α-helical structure of the peptide
and its ability to associate with oxidized lipids as demonstrated in the
present work for the ﬁrst time help explain the previously observed
anti-inﬂammatory and anti-atherosclerotic properties. Reﬁnement of
this structure using new peptide analogs may yield novel highly
effective and easily synthesizable peptides in large amounts for the
inhibition and treatment of atherosclerosis and other inﬂammatory
diseases.
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